<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gadopentetate dimeglumine (United States: Not available): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gadopentetate dimeglumine (United States: Not available): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Gadopentetate dimeglumine (United States: Not available): Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="8881" href="/d/html/8881.html" rel="external">see "Gadopentetate dimeglumine (United States: Not available): Drug information"</a> and <a class="drug drug_patient" data-topicid="11743" href="/d/html/11743.html" rel="external">see "Gadopentetate dimeglumine (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52867012"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Magnevist</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1015753"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Diagnostic Agent</span>;</li>
<li>
<span class="list-set-name">Gadolinium-Containing Contrast Agent</span>;</li>
<li>
<span class="list-set-name">Radiological/Contrast Media, Ionic</span>;</li>
<li>
<span class="list-set-name">Radiological/Contrast Media, Paramagnetic Agent</span></li></ul></div>
<div class="block dop drugH1Div" id="F175105"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing presented in mL/kg and mmol/kg; use caution. Parenteral solution contains 0.5 mmol/mL of gadopentetate dimeglumine.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="739c16cf-32eb-4b4c-b7a5-d2bf339a7d4f">Body, CNS, head, and neck magnetic resonance imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Body, CNS, head, and neck magnetic resonance imaging: </b>Children ≥2 years and Adolescents: IV: 0.2 mL/kg (0.1 mmol/kg); imaging must be completed within 1 hour of injection. <b>Note:</b> Dosing for patients &gt;130 kg (286 pounds) has not been studied.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51112193"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">GFR &gt;30 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling; use with caution; acute kidney injury requiring dialysis has been reported with use in patients with chronic renal dysfunction; risk may be increased with higher doses of contrast agent. Risk for nephrogenic systemic fibrosis (NSF) development increases as renal function decreases.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Use contraindicated.</p>
<p style="text-indent:-2em;margin-left:4em;">Dialysis: There are no pediatric-specific recommendations; based on experience in adult patients, the following has been observed:</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis: If administered to patients already receiving hemodialysis, consider prompt hemodialysis following exposure (eg, within 3 hours) (Kuo 2007). Data has shown hemodialysis enhances gadolinium elimination with average gadolinium excretory rates of 78%, 96%, and 99% in the first, second, and third hemodialysis sessions, respectively (Kuo 2007; Okada 2001).</p>
<p style="text-indent:-2em;margin-left:6em;">Peritoneal dialysis: Likely to be less efficient at clearing gadolinium (Joffe 1998; Kuo 2007).</p></div>
<div class="block dohp drugH1Div" id="F51112194"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; does not undergo significant hepatic metabolism.</p></div>
<div class="block doa drugH1Div" id="F175099"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8881" href="/d/html/8881.html" rel="external">see "Gadopentetate dimeglumine (United States: Not available): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b5d10967-0b00-4a0c-b053-4ae44771d019">CNS, head, and neck imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>CNS, head, and neck imaging:</b> IV: 0.1 mmol/kg (0.2 mL/kg) (maximum single dose: 20 mL); may repeat within 30 minutes if clinically indicated.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990470"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">GFR &gt;30 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Risk for NSF development increases as renal function decreases.</p>
<p style="text-indent:-2em;margin-left:2em;">GFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Use contraindicated.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: If administered to patients already receiving hemodialysis, consider prompt hemodialysis following exposure (eg, within 3 hours) (Kuo 2007). Data has been shown hemodialysis enhances gadolinium elimination with average gadolinium excretory rates of 78%, 96%, and 99% in the first, second, and third hemodialysis sessions, respectively (Kuo 2007; Okada 2001).</p>
<p style="text-indent:-2em;margin-left:2em;">Peritoneal dialysis: Likely to be less efficient at clearing gadolinium (Joffe 1998; Kuo 2007).</p></div>
<div class="block doha drugH1Div" id="F50987720"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: There are no dosage adjustments provided in the manufacturer’s labeling; does not undergo significant hepatic metabolism.</p></div>
<div class="block adr drugH1Div" id="F175078"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (5%), sensation of cold (localized: ≤2%; includes injection site), dizziness (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abdominal distress, abdominal pain, acute renal failure, agitation, altered sense of smell, anaphylactic shock, anaphylactoid reaction, anaphylaxis, angioedema, anxiety, arthralgia, asthenia, auditory impairment, back pain, bronchospasm, cardiac arrhythmia, chest tightness, chills, coma, conjunctivitis, cough, cyanosis, decreased body temperature, decreased heart rate, deep vein thrombosis, diaphoresis, diarrhea, diplopia, drowsiness, dysgeusia, dyspnea, erythema multiforme, eye irritation, eye pain, facial edema, fatigue, fever, hypertension, hypotension, increased body temperature, increased thirst, injection site reaction (burning sensation at injection site, compartment syndrome, connective tissue disease [fasciitis], localized edema, pain at injection site, phlebitis, skin and soft tissue necrosis, thrombosis, warm sensation at injection site), lacrimation, laryngeal edema, laryngospasm, loss of consciousness, migraine, nephrogenic systemic fibrosis, otalgia, pallor, paresthesia, pharyngeal edema, pruritus, pulmonary edema, pustules, renal insufficiency, respiratory distress, rhinitis, seizure, sensation of cold (generalized), shivering, shock, sialorrhea, skin changes (plaques), skin rash, sneezing, speech disturbance, substernal pain, syncope, tachycardia, throat irritation, thrombophlebitis, toothache, tremor, type IV hypersensitivity reaction, urinary incontinence, urinary urgency, urticaria, vasodilation, visual disturbance, vomiting, xerostomia</p></div>
<div class="block coi drugH1Div" id="F175089"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to gadopentetate dimeglumine or any component of the formulation; chronic severe kidney disease (GFR &lt;30 mL/minute/1.73 m<sup>2</sup>); acute kidney injury; neonates up to 4 weeks of age due to their immature renal function.</p></div>
<div class="block war drugH1Div" id="F175076"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Vesicant; ensure proper needle/catheter/line placement prior to and during administration. Monitor infusion site. Avoid extravasation. Skin and soft tissue necrosis, thrombosis, fasciitis, and compartment syndrome have occurred (rare) at injection site or limb used for injection; phlebitis and thrombophlebitis may be observed usually within 24 hours of injection and resolves with supportive treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gadolinium retention: Gadolinium is retained for months or years in brain, bone, skin, and other organs (kidney, liver, spleen); the highest concentration and longest duration have been found in the bone. Linear GBCAs (gadodiamide and gadoversetamide &gt; gadoxetate disodium, gadopentetate dimeglumine, and gadobenate dimeglumine) result in more retention than macrocyclic GBCAs (gadoterate meglumine, gadobutrol, and gadoteridol). Pathologic and clinical consequences of gadolinium retention in skin and other organs have been established in patients with impaired renal function; there also have been rare reports of pathologic skin changes in patients with normal renal function. Consequences of gadolinium retention in the brain or in patients with normal renal function have not been established. Patients with normal renal function that may be at higher risk for gadolinium retention include: patients requiring multiple lifetime doses, pregnant and pediatric patients, and patients with inflammatory conditions; take GBCA retention characteristics into consideration for these patients. Minimize repetitive GBCA imaging studies.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity, including anaphylactic reactions (rare), may occur; appropriate equipment (eg, ventilator) and emergency medications (eg, epinephrine) should be available during use. Delayed reactions may also occur (within several hours of administration). Patients with a history of allergic reactions and/or bronchial asthma may be at an increased risk for developing hypersensitivity reactions; use caution in these patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephrogenic systemic fibrosis: <b>[Canadian Boxed Warning]</b>
<b>: Gadolinium-based contrast agents (GBCAs) exposure may increase the risk for nephrogenic systemic fibrosis (NSF) in patients with renal impairment; avoid use unless GBCA enhanced imaging is essential for diagnostic purposes. Use is contraindicated in patients with acute kidney injury or chronic, severe renal disease (GFR &lt;30 mL/minute/1.73 m<sup>2</sup>), and neonates up to 4 weeks of age.</b> The risk appears lower in patients with moderate, chronic renal disease (GFR 30 to 59 mL/minute/1.73 m<sup>2</sup>) and little, if any, in patients with mild, chronic renal disease (GFR 60 to 89 mL/minute/1.73 m<sup>2</sup>). NSF, a potentially fatal disease, affects the skin, muscle, and internal organs. All patients should be screened for renal dysfunction prior to administration; estimate GFR through laboratory testing in patients at risk for chronic renal disease (diabetes, chronic hypertension, age &gt;60 years). In patients at risk of NSF, do not exceed the recommended dosage and allow sufficient time (ie, several half-lives) for elimination prior to readministration (avoidance of readministration is preferred). In patients receiving hemodialysis, consider prompt initiation of hemodialysis following administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; contraindicated in patients with acute kidney injury or chronic, severe renal impairment (GFR &lt;30 mL/minute/1.73 m<sup>2</sup>). Dose-dependent worsening of renal function or acute renal failure has occurred in patients with renal insufficiency, generally within 48 hours following administration. Evaluate renal function in patients with renal impairment prior to use; consider follow-up monitoring.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Scan interpretation: Use caution when interpreting a contrast-enhanced scan in the absence of a companion unenhanced noncontrast MRI.</p></div>
<div class="block prod-avail drugH1Div" id="F58898153"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the United States.</p></div>
<div class="block geq drugH1Div" id="F175074"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323164"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Magnevist Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">469.01 mg/mL (per mL): $5.04</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867013"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Magnevist: 469.01 mg/mL (10 mL, 15 mL, 20 mL) [contains meglumine, pentetic acid (dtpa)]</p></div>
<div class="block admp drugH1Div" id="F52612900"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Dose should be administered at a rate not to exceed 10 mL per 15 seconds. Complete imaging procedure within 1 hour of injection. Following administration, flush line with NS 5 mL.</p>
<p style="text-indent:0em;margin-top:2em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect; remove needle/cannula; elevate extremity. Aspiration of extravasated contrast media is not recommended (ACR 2018). Information conflicts regarding the use of hyaluronidase; the American College of Radiology (ACR) Manual on Contrast Media does not recommend hyaluronidase in the management of contrast media extravasation (ACR 2018); other sources suggest its utility in extravasation management (Bellin 2002; Reynolds 2014) (see Management of Drug Extravasations for more details).</p></div>
<div class="block adm drugH1Div" id="F175086"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Dose should be administered at a rate not to exceed 10 mL per 15 seconds. Complete imaging procedure within 1 hour of injection. Following administration, flush line with NS 5 mL.</p>
<p style="text-indent:0em;margin-top:2em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect; remove needle/cannula; elevate extremity. Aspiration of extravasated contrast media is not recommended (ACR 2023). Information conflicts regarding the use of hyaluronidase; the American College of Radiology (ACR) Manual on Contrast Media does not recommend hyaluronidase in the management of contrast media extravasation (ACR 2023); other sources suggest its utility in extravasation management for inoperable cases with compartment syndrome (Stefanos 2023).</p>
<p style="text-indent:-2em;margin-left:4em;margin-top:2em;">
<i>If using hyaluronidase:</i>
<b>Intradermal or SUBQ</b>: Dose varies based on the size of infiltration; inject a total of 5 to 250 units (~100 mL contrast reabsorbed per 15 units of hyaluronidase) around the site of extravasation (Stefanos 2023).</p></div>
<div class="block sts drugH1Div" id="F175094"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 15°C to 30°C (59°F to 86°F). Protect from light. Discard if not used within 24 hours of opening.</p></div>
<div class="block usep drugH1Div" id="F53567044"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Contrast medium for magnetic resonance imaging (MRI) to visualize CNS lesions with abnormal vascularity in the brain, spine, and associated tissues; extracranial/extraspinal lesions with abnormal vascularity in the head and neck; and body lesions with abnormal vascularity (All indications: FDA approved in ages ≥2 years and adults)</p></div>
<div class="block mst drugH1Div" id="F58898152"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">
<b>ALERT: Canadian Boxed Warning: </b>Health Canada-approved labeling includes a boxed warning. See "Warnings/Precautions" section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299379"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6220551"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F175090"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Gadopentetate dimeglumine crosses the placenta (Marcos 1997).</p>
<p style="text-indent:0em;margin-top:2em;">Pregnant patients may be at increased risk for gadolinium retention. Use of gadolinium-based contrast agents in pregnancy is controversial and should be limited. A gadolinium-based contrast agent with MRI may be considered for use in pregnancy if it will significantly improve diagnostic performance and is expected to improve fetal or maternal outcome (ACOG 723 2017). In addition, use should only be considered if information needed from the MRI study cannot be acquired without using a contrast agent and cannot be deferred until after delivery. Agents with a low risk for development of nephrogenic systemic fibrosis should be used at the lowest effective dose (ACR 2023).</p></div>
<div class="block mopp drugH1Div" id="F53567033"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor renal function (prior to administration); signs of hypersensitivity (during and for several hours after procedure); injection site for extravasation; short- and long-term monitoring of signs and symptoms of NSF (eg, burning, itching, swelling, hardening and/or tightening of skin, joint stiffness, deep hip or rib bone pain, muscle weakness, limited range of motion, and/or yellowed/raised spots on whites of eye)</p></div>
<div class="block pha drugH1Div" id="F175075"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Exposure to an external magnetic field induces a large local magnetic field in gadopentetate exposed tissues. This local magnetism disrupts water protons in the vicinity, resulting in a change in proton density and spin characteristics, which can be detected by the imaging device.</p></div>
<div class="block phk drugH1Div" id="F175088"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 266 ± 43 mL/kg; does not cross intact blood-brain barrier; distribution half-life: 0.2 ± 0.13 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 1.6 ± 0.13 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥60 mL/minute: 2.6 ± 1.2 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 30 to &lt;60 mL/minute: 4.2 ± 2 hours</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: 10.8 ± 6.9 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">OR</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate kidney impairment: 3 to 4 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe kidney impairment: ~11 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~91% as gadopentetate within 24 hours).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038645"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Magnevist</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Magnevist | Opacite | Viewgam</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Magnegita | Magnetolux | Magnevist</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Magnevist</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Magnevist</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Magnegita | Magnevist</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Magnevistan | Viewgam</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Magnevist | Magnograf</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Gadopentetate dime | Gadopentetic acid | Magnevist | Meglumine gadopent</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Magnevist</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Gadocon | Gadopent | Gadothek | Magnevist | Magnograf</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Magnevist | Pentaglubine</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Magnevist</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Magnegita | Magnevist</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Magnevist</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Magnevist | Magnograf</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Gadopentetate dimeglumine</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Magnevist</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Magnevist</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Magnevist</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Magnegita | Magnetolux | Magnevist</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Magnevist</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Magnevist</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Magnevist</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Magnevist | Magnilek | Magniscan</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Magnegita | Magnevist</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Magnevist</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Magnevist</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Magnevist | Magnilek</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Magnevist | Mrbester</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Magnegita | Magnevist</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Magnegita | Magnevist</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Magnevist</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Magnevist</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Magnevist</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Magnevist</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Magnevist</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Magnevist</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Magnevist</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Magnevist</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Magnevist | Viewgam</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Magnevist</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Magnevist</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Gadopentetic acid tl | Magnevist</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Magnevist</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Magnevist</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Magnevist</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Magnetolux | Magnevist</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Magnevist</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Magnevist</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Emaray | Magnevist</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Magnevist</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Magnevist | Tomovist</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Magnevist</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Magnevist</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-28937575">
<a name="28937575"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice. Committee Opinion No. 723: guidelines for diagnostic imaging during pregnancy and lactation. <i>Obstet Gynecol</i>. 2017;130(4):e210-e216. Erratum in: <i>Obstet Gynecol</i>. 2018;132(3):786.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadopentetate-dimeglumine-united-states-not-available-pediatric-drug-information/abstract-text/28937575/pubmed" id="28937575" target="_blank">28937575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACT.1">
<a name="ACT.1"></a>American College of Radiology (ACR) Committee on Drugs and Contrast Media. ACR manual on contrast media. https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf. Published 2023. Accessed May 17, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12386778">
<a name="12386778"></a>Bellin MF, Jakobsen JA, Tomassin I, et al; Contrast Media Safety Committee Of The European Society Of Urogenital Radiology. Contrast medium extravasation injury: guidelines for prevention and management. <i>Eur Radiol</i>. 2002;12(11):2807-2812. doi: 10.1007/s00330-002-1630-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadopentetate-dimeglumine-united-states-not-available-pediatric-drug-information/abstract-text/12386778/pubmed" id="12386778" target="_blank">12386778</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control, “Nephrogenic Fibrosing Dermopathy Associated with Exposure to Gadolinium-Containing Contrast Agents: St. Louis, Missouri,” <i>MMWR Weekly Rep</i>, 2007, 56(07):137-141.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23345200">
<a name="23345200"></a>Expert Panel on MR Safety, "ACR Guidance Document on MR Safe Practices: 2013," <i>J Magn Reson Imaging</i>, 2013, 37(3):501-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadopentetate-dimeglumine-united-states-not-available-pediatric-drug-information/abstract-text/23345200/pubmed" id="23345200" target="_blank">23345200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16431890">
<a name="16431890"></a>Grobner T, “Gadolinium - A Specific Trigger for the Development of Nephrogenic Fibrosing Dermopathy and Nephrogenic Systemic Fibrosis,” <i>Nephrol Dial Transplant</i>, 2006, 21(4):1104-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadopentetate-dimeglumine-united-states-not-available-pediatric-drug-information/abstract-text/16431890/pubmed" id="16431890" target="_blank">16431890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9653466">
<a name="9653466"></a>Joffe P, Thomsen HS, and Meusel M, "Pharmacokinetics of Gadodiamide Injection in Patients with Severe Renal Insufficiency and Patients Undergoing Hemodialysis or Continuous Ambulatory Peritoneal Dialysis," <i>Acad Radiol</i>, 1998, 5(7):491-502.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadopentetate-dimeglumine-united-states-not-available-pediatric-drug-information/abstract-text/9653466/pubmed" id="9653466" target="_blank">9653466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10924585">
<a name="10924585"></a>Kubik-Huch RA, Gottstein-Aalame NM, Frenzel T, et al. Gadopentetate dimeglumine excretion into human breast milk during lactation. <i>Radiology</i>. 2000;216(2):555-558.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadopentetate-dimeglumine-united-states-not-available-pediatric-drug-information/abstract-text/10924585/pubmed" id="10924585" target="_blank">10924585</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17213364">
<a name="17213364"></a>Kuo PH, Kanal E, Abu-Alfa AK, et al, "Gadolinium-Based MR Contrast Agents and Nephrogenic Systemic Fibrosis," <i>Radiology</i>, 2007, 242(3):647-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadopentetate-dimeglumine-united-states-not-available-pediatric-drug-information/abstract-text/17213364/pubmed" id="17213364" target="_blank">17213364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6628223">
<a name="6628223"></a>MacCara ME. Extravasation: a hazard of intravenous therapy. <i>Drug Intell Clin Pharm</i>. 1983;17(10):713-717.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadopentetate-dimeglumine-united-states-not-available-pediatric-drug-information/abstract-text/6628223/pubmed" id="6628223" target="_blank">6628223</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Magnevist (gadopentetate dimeglumine) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc; April 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9356634">
<a name="9356634"></a>Marcos HB, Semelka RC, and Worawattanakul S, "Normal Placenta: Gadolinium-Enhanced Dynamic MR Imaging," <i>Radiology</i>, 1997, 205(2):493-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadopentetate-dimeglumine-united-states-not-available-pediatric-drug-information/abstract-text/9356634/pubmed" id="9356634" target="_blank">9356634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11350296">
<a name="11350296"></a>Okada S, Katagiri K, Kumazaki T, et al, “Safety of Gadolinium Contrast Agent in Hemodialysis Patients,” <i> Acta Radiol</i>, 2001, 42(3):339-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadopentetate-dimeglumine-united-states-not-available-pediatric-drug-information/abstract-text/11350296/pubmed" id="11350296" target="_blank">11350296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24420913">
<a name="24420913"></a>Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632. doi: 10.1002/phar.1396.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadopentetate-dimeglumine-united-states-not-available-pediatric-drug-information/abstract-text/24420913/pubmed" id="24420913" target="_blank">24420913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8428080">
<a name="8428080"></a>Rofsky NM, Weinreb JC, Litt AW. Quantitative analysis of gadopentetate dimeglumine excreted in breast milk. <i>J Magn Reson Imaging</i>. 1993;3(1):131-132.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadopentetate-dimeglumine-united-states-not-available-pediatric-drug-information/abstract-text/8428080/pubmed" id="8428080" target="_blank">8428080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22633726">
<a name="22633726"></a>Rowlett J. Extravasation of contrast media managed with recombinant human hyaluronidase. <i>Am J Emerg Med</i>. 2012;30(9):2102.e1-3. doi: 10.1016/j.ajem.2012.03.005.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadopentetate-dimeglumine-united-states-not-available-pediatric-drug-information/abstract-text/22633726/pubmed" id="22633726" target="_blank">22633726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2110745">
<a name="2110745"></a>Schmiedl U, Maravilla KR, Gerlach R, Dowling CA. Excretion of gadopentetate dimeglumine in human breast milk. <i>AJR Am J Roentgenol</i>. 1990;154(6):1305-1306.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadopentetate-dimeglumine-united-states-not-available-pediatric-drug-information/abstract-text/2110745/pubmed" id="2110745" target="_blank">2110745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy</i>. 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadopentetate-dimeglumine-united-states-not-available-pediatric-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22403117">
<a name="22403117"></a>Tremblay E, Thérasse E, Thomassin-Naggara I, et al, "Quality Initiatives: Guidelines for Use of Medical Imaging During Pregnancy and Lactation," <i>Radiographics</i>, 2012, 32(3):897-911.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadopentetate-dimeglumine-united-states-not-available-pediatric-drug-information/abstract-text/22403117/pubmed" id="22403117" target="_blank">22403117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22451541">
<a name="22451541"></a>Wang PI, Chong ST, Kielar AZ, et al, "Imaging of Pregnant and Lactating Patients: Part 1, Evidence-Based Review and Recommendations," <i>AJR Am J Roentgenol</i>, 2012, 198(4):778-84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadopentetate-dimeglumine-united-states-not-available-pediatric-drug-information/abstract-text/22451541/pubmed" id="22451541" target="_blank">22451541</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Wanko SO, Telen MJ, “Transfusion Management in Sickle Cell Disease,” <i>Hematol Oncol Clin N Am</i>, 2005, 19(5):803-26.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15609057">
<a name="15609057"></a>Webb JA, Thomsen HS, and Morcos SK, "The Use of Iodinated and Gadolinium Contrast Media During Pregnancy and Lactation," <i>Eur Radiol</i>, 2005, 15(6):1234-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadopentetate-dimeglumine-united-states-not-available-pediatric-drug-information/abstract-text/15609057/pubmed" id="15609057" target="_blank">15609057</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Widmark JM, “Imaging-related Medications: A Class Overview,” <i>Proc (Bayl Univ Med Cent)</i>, 2007, 20(4):408-17.</div>
</li>
<li>
<div class="reference">
                  Zenk KE. Management of intravenous extravasations. <i>Infusion</i>. 1981;5(4):77-79.</div>
</li></ol></div><div id="topicVersionRevision">Topic 103681 Version 91.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
